Sanara MedTech director granted 4,616 restricted shares

Ortwein Sara N reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Ortwein Sara N reported acquisition or exercise transactions in this Form 4 filing.

Sanara MedTech Inc. director Sara N. Ortwein received a grant of 4,616 shares of common stock as restricted stock under the company’s 2024 Omnibus Long-Term Incentive Plan. These shares were awarded at no cash cost and increase her direct holdings to 25,415 shares.

The restricted stock will vest on the earlier of the company’s 2027 annual shareholder meeting or June 4, 2027, as long as she continues providing specified services to Sanara MedTech through that date. This filing reflects a compensation-related equity award rather than an open-market share purchase or sale.

Insider Trade Summary

Grant/Award: 4,616 shares

Grant/Award 1 txn

Insider Ortwein Sara N

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	4,616	$0.00	$0.00

Holdings After Transaction: Common Stock — 25,415 shares (Direct)

Footnotes (1)

1. F1. Represents shares of restricted stock granted by Sanara MedTech Inc. (the "Issuer") to the reporting person pursuant to the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan. The restricted stock will vest on the earlier of (i) the date of the 2027 annual shareholder meeting or (ii) June 04, 2027, provided that the reporting person is providing certain services to the Issuer through such date.

Key Figures

Restricted stock grant: 4,616 shares Price per share for grant: $0.0000 per share Total shares after grant: 25,415 shares +2 more

5 metrics

Restricted stock grant 4,616 shares Common Stock award on June 4, 2026

Price per share for grant $0.0000 per share Reported grant price (compensation award)

Total shares after grant 25,415 shares Direct holdings following the transaction

Vesting outside date June 4, 2027 Latest vesting date for restricted stock

Vesting alternative event 2027 annual shareholder meeting Earlier vesting trigger if before June 4, 2027

Key Terms

restricted stock, 2024 Omnibus Long-Term Incentive Plan, annual shareholder meeting, vest

4 terms

restricted stock financial

"Represents shares of restricted stock granted by Sanara MedTech Inc."

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

2024 Omnibus Long-Term Incentive Plan financial

"pursuant to the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan."

annual shareholder meeting financial

"will vest on the earlier of (i) the date of the 2027 annual shareholder meeting"

A yearly gathering where a company’s owners (shareholders) and its leaders meet to review performance, approve key decisions like electing directors, and vote on issues such as executive pay or major policy changes. Think of it as an annual town hall for people who own part of the business: investors use it to ask questions, influence direction through votes, and gauge management’s plans and transparency, all of which can affect the stock’s outlook.

vest financial

"The restricted stock will vest on the earlier of"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Sanara MedTech (SMTI) report for Sara N. Ortwein?

Sanara MedTech reported that director Sara N. Ortwein received a grant of 4,616 shares of restricted common stock. The award was part of the 2024 Omnibus Long-Term Incentive Plan and did not involve an open-market purchase or sale.

How many Sanara MedTech (SMTI) shares does Sara N. Ortwein hold after this Form 4?

After the restricted stock grant, Sara N. Ortwein directly holds 25,415 shares of Sanara MedTech common stock. This total includes the newly granted 4,616 restricted shares, which are subject to future vesting conditions through 2027.

When do the newly granted restricted shares in Sanara MedTech (SMTI) vest?

The 4,616 restricted shares will vest on the earlier of the 2027 annual shareholder meeting or June 4, 2027. Vesting requires that Sara N. Ortwein continue providing certain services to Sanara MedTech through the applicable vesting date.

Was cash paid for the Sanara MedTech (SMTI) restricted stock granted to Sara N. Ortwein?

No cash was paid for this award. The 4,616 restricted shares were granted at a reported price per share of $0.0000, reflecting a compensation-related equity grant rather than a purchase in the open market.

What plan governs the restricted stock grant to Sara N. Ortwein at Sanara MedTech (SMTI)?

The restricted stock grant was issued under the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan. This plan authorizes equity-based compensation awards, including restricted stock, to directors and other service providers of the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 08:31 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ortwein Sara N

(Last) (First) (Middle)

1200 SUMMIT AVE SUITE 414

(Street)

FORT WORTH TEXAS 76102

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Sanara MedTech Inc. [ SMTI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/04/2026		A		4,616(1)	A	$0	25,415	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of restricted stock granted by Sanara MedTech Inc. (the "Issuer") to the reporting person pursuant to the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan. The restricted stock will vest on the earlier of (i) the date of the 2027 annual shareholder meeting or (ii) June 04, 2027, provided that the reporting person is providing certain services to the Issuer through such date.

	/s/ Sara N. Ortwein	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)